BioGaia invests in Sweden – launches its entire adult health portfolio
BioGaia Osfortis for bone health(1) and BioGaia Prodentis for the mouth(2) are now launched in Sweden. By this, BioGaia's entire adult health portfolio is now available on the domestic market.
"In line with our already communicated strategy to accelerate the roll-out of our products for adults, we are pleased to now be able to offer the entire adult health portfolio to Swedish consumers," says Isabelle Ducellier, CEO of BioGaia.
BioGaia Osfortis and BioGaia Prodentis – two new and innovative products
BioGaia Osfortis capsules contain the clinically tested and patented lactic acid bacterium L. reuteri ATCC PTA 6475 and vitamin D3 which helps to maintain a normal bone structure.
BioGaia Prodentis lozenges are successfully sold in around 40 countries worldwide. BioGaia Prodentis contains the patented lactic acid bacteria L. reuteri DSM 17938 and ATCC PTA 5289 and has been tested in more than 50 clinical studies.
Some of BioGaia's largest products are already on the Swedish market:
- BioGaia Protectis capsules and chewable tablets are available in several pack sizes and product variants. The tablets are also available with 10 or 20 µg of vitamin D3 which contributes to the normal function of the immune system.
- BioGaia Gastrus chewable tablets with mandarin flavor.
All products are sold via apotea.se and MEDS.se. In the future, the products will be available in more pharmacy chains, both online and in physical stores. Read more about BioGaia's products in Sweden at produkter.biogaia.se.
Latest press releases from BioGaia
30.11.2020 Number of shares and votes in BioGaia
25.11.2020 Extraordinary General Meeting of BioGaia
03.11.2020 Nominating Committee ahead of the BioGaia AGM 6 May 2021
1) Vitamin D contributes to the maintenance of normal bones.
2) Consumption of foods containing isomalt and sucralose instead of sugar contributes to the maintenance of tooth mineralisation.
This product should not be a substitute for a varied and balanced diet and healthy lifestyle.
For additional information please contact
Isabelle Ducellier, CEO: +46 8 555 293 00
BioGaia is a Swedish world-leading probiotic company that has been at the forefront of microbiome research for more than 30 years. BioGaia develops, markets and sells probiotic products with documented health benefits. To date, over 200 articles on clinical trials with BioGaia's probiotic strains have been published. The products are sold by nutrition and pharmaceutical companies in more than 100 countries. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. www.biogaia.com